Cargando…

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States

BACKGROUND: Chronic lymphocytic leukemia (CLL) is a significant health and economic burden in the United States. Treatments include chemoimmunotherapy, such as obinutuzumab (G) plus chlorambucil (Clb) or bendamustine plus rituximab (BR), and chemotherapy-free regimens incorporating oral targeted the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatterjee, Anuja, Shapouri, Sheila, Manzoor, Beenish S, Ravelo, Arliene, Sail, Kavita, Qendri, Venetia, van de Wetering, Gijs, Davids, Matthew S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391182/ https://www.ncbi.nlm.nih.gov/pubmed/34714110 http://dx.doi.org/10.18553/jmcp.2021.27.11.1532

Ejemplares similares

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
por: Chatterjee, Anuja, et al.
Publicado: (2022)

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
por: Munir, Talha, et al.
Publicado: (2023)

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
por: Allan, J. N., et al.
Publicado: (2022)

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
por: Samuels, Courtney, et al.
Publicado: (2021)

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
por: Pratz, Keith W., et al.
Publicado: (2022)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

The Unfit
por: Sinclair, W. J. H.
Publicado: (1911)

The Unfit
Publicado: (1911)

PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX-AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY
por: Rahimi, Muhammad Naim Bin Che, et al.
Publicado: (2023)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
por: Le Gouill, Steven, et al.
Publicado: (2023)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
por: Shukla, Deepak Kumar, et al.
Publicado: (2021)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

The successful combination of grapefruit juice and venetoclax in an unfit acute myeloid leukemia patient with adverse risk: A case report
por: Long, Zhangbiao, et al.
Publicado: (2022)

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML
por: Chen, Xiaotong, et al.
Publicado: (2023)

P1713: VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
por: Kanevsky, D., et al.
Publicado: (2022)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

The Marriage of the Unfit
Publicado: (1898)

The Sterilsation of the Unfit
Publicado: (1913)

Sterilization of the Unfit
por: Bristowe, H. C.
Publicado: (1931)

National "Unfits"
Publicado: (1920)

Multiplication of the Unfit
Publicado: (1921)

Asexualization of the Unfit
Publicado: (1912)

The Marriage of the Unfit
por: Campbell, Harry
Publicado: (1898)

Sterilization of the Unfit
por: Bogart, G. Henri
Publicado: (1912)

Sterilizing the Unfit
por: Bogart, G. Henri
Publicado: (1912)

Sterilization of the Unfit
por: Bogart, G. Henri
Publicado: (1910)

Asexualization of the Unfit
Publicado: (1912)

Sterilizing the Unfit
por: Bogart, G. Henri
Publicado: (1913)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

Pricing of HPV vaccines in European tender-based settings
por: Qendri, Venetia, et al.
Publicado: (2018)

Who Will Benefit From Expanding HPV Vaccination Programs to Boys?
por: Qendri, Venetia, et al.
Publicado: (2018)

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
por: Zhang, Keyuan, et al.
Publicado: (2023)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
por: Hengeveld, P. J., et al.
Publicado: (2023)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
por: Wei, Wenjian, et al.
Publicado: (2023)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tbahl2of67v3np9643ceou2577